血嗜酸性粒细胞与慢阻肺维持治疗反应:FLAME试验数据
FLAME试验预设分析比较茚达特罗/格隆溴铵与沙美特罗/氟替卡松预防慢阻肺急性加重,按血嗜酸性粒细胞百分比和绝对计数分层。结果显示茚达特罗/格隆溴铵在多个嗜酸性粒细胞亚组中显著优于沙美特罗/氟替卡松,且沙美特罗/氟替卡松肺炎发生率更高。
要点
- 茚达特罗/格隆溴铵在血嗜酸性粒细胞<2%、≥2%、<3%、<5%及<150 cells/μl亚组中预防急性加重均显著优于沙美特罗/氟替卡松。
- 任何嗜酸性粒细胞切点下沙美特罗/氟替卡松均未优于茚达特罗/格隆溴铵。
- 沙美特罗/氟替卡松肺炎发生率在<2%和≥2%亚组中均高于茚达特罗/格隆溴铵。
核心结论
- 在慢阻肺患者中,无论血嗜酸性粒细胞水平如何,茚达特罗/格隆溴铵对急性加重的预防效果优于或类似于沙美特罗/氟替卡松。
研究设计与样本
- FLAME试验的预设分析,比较每日一次茚达特罗/格隆溴铵110/50 μg与每日两次沙美特罗/氟替卡松50/500 μg。
- 纳入前一年至少有一次急性加重的慢阻肺患者。
主要发现
- 茚达特罗/格隆溴铵在<2%、≥2%、<3%、<5%和<150 cells/μl亚组中预防所有严重程度及中重度急性加重均显著优于沙美特罗/氟替卡松。
- 任何切点下沙美特罗/氟替卡松均未优于茚达特罗/格隆溴铵。
- 中重度急性加重率未随血嗜酸性粒细胞升高而增加。
- 沙美特罗/氟替卡松肺炎发生率在<2%和≥2%亚组中均高于茚达特罗/格隆溴铵。
关键数值与推荐
- 血嗜酸性粒细胞百分比切点:<2%与≥2%、<3%与≥3%、<5%与≥5%。
- 血嗜酸性粒细胞绝对计数分层:<150 cells/μl、150至<300 cells/μl、≥300 cells/μl。
临床怎么用
- 对于有急性加重史的慢阻肺患者,选择茚达特罗/格隆溴铵预防急性加重不依赖于血嗜酸性粒细胞水平。
局限性
- 部分分析为事后分析,需进一步研究验证其他切点和终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD). OBJECTIVES: We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an inhaled corticosteroid/long-acting β2-agonist combination versus a long-acting β2-agonist/long-acting muscarinic antagonist combination for exacerbation prevention. METHODS: We conducted prespecified analyses of data from the FLAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily long-acting β2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50 μg with twice-daily long-acting β2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 μg in patients with one or more exacerbations in the preceding year. Subsequent post hoc analyses were conducted to address further cutoffs and endpoints. MEASUREMENTS AND MAIN RESULTS: We compared treatment efficacy according to blood eosinophil percentage (<2% and ≥2%, <3% and ≥3%, and <5% and ≥5%) and absolute blood eosinophil count (<150 cells/μl, 150 to <300 cells/μl, and ≥300 cells/μl). Indacaterol/glycopyrronium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all severities, or moderate or severe) in the <2%, ≥2%, <3%, <5%, and <150 cells/μl subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium. Furthermore, the rate of moderate or severe exacerbations did not increase with increasing blood eosinophils. The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the <2% and ≥2% subgroups. CONCLUSIONS: Our prospective analyses indicate that indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD. Clinical trial registered with www.clinicaltrials.gov (NCT01782326).
引用
- Roche N, Chapman KR, Vogelmeier CF, et al. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. Am J Respir Crit Care Med. 2017. PMID: 28278391. doi:10.1164/rccm.201701-0193OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。